Publication Name	World Journal of Hematology
Manuscript ID	1878
Country	Netherlands

Received	2013-01-11 08:57
Peer-Review Started	2013-01-11 14:25
To Make the First Decision	2013-02-26 14:48
Return for Revision	2013-04-10 08:51
Revised
Second Decision	2013-06-18 09:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-06-18 23:58
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-07-15 15:37
Publish the Manuscript Online	2013-07-25 22:33

ISSN	2218-6204 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Review
Article Title	PVSG and WHO vs European Clinical, Molecular and Pathological Criteria for prefibrotic myeloproliferative neoplasms
Manuscript Source	Invited Manuscript
All Author List	Jan Jacques Michiels, Zwi Berneman, Wilfried Schroyens, King H Lam and Hendrik De Raeve
Funding Agency and Grant Number
Corresponding Author	Jan Jacques Michiels, MD, PhD, Senior Internist, European Working Group on Myeloproliferative Neoplasms, Goodheart Institute, Erasmus Tower, Veenmos 13, 3069 AT, Rotterdam, The Netherlands. goodheartcenter@upcmail.nl
Key Words	Myeloproliferative neoplasms; Essential thrombocythemia; Prodromal polycythemia vera; Polycythemia vera; Myelofibrosis; JAK2V617F mutation; JAK2 wild type myeloproliferative neoplasm; Bone marrow pathology
Core Tip	The integrated World Health Organization (WHO) and European Clinical, Molecular and Pathological classification of the myeloproliferative neoplasms include JAK2V617F mutated normocellular essential thrombocythemia (WHO-ET), prodromal polycythemia vera (PV), classical PV, and hypercellular ET due to megakaryocytic, granulocytic myeloproliferation. Evolution of prodromal PV into overt PV is common. JAK2/MPL wild hypercellular ET associated with prefibrotic primary megakaryocytic and granulocytic myeloproliferation is characterized by densely clustered immature dysmorphic megakaryocytes with bulky (bulbous) hyperchromatic nuclei, which are never seen in JAK2V617F mutated ET and PV, and also not in JAK2 wild type normocellular ET (WHO-ET) carrying the MPL515 mutation.
Publish Date	2013-07-25 22:33
Citation	Michiels JJ, Berneman Z, Schroyens W, Lam KH, De Raeve H. PVSG and WHO vs ECMP criteria for prefibrotic myeloproliferative neoplasms. World J Hematol 2013; 2(3): 71-88
URL	http://www.wjgnet.com/2218-6204/full/v2/i3/71.htm
DOI	http://dx.doi.org/10.5315/wjh.v2.i3.71

Full Article (PDF)	WJH-2-71.pdf
Manuscript File	1878-Review.docx
Answering Reviewers	1878-Answering reviewers.doc
Copyright License Agreement	1878-Copyright assignment.pdf
Peer-review Report	1878-Peer review(s).pdf
Scientific Editor Work List	1878-Scientific editor work list.doc